These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 25455994

  • 1. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP.
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [Abstract] [Full Text] [Related]

  • 2. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
    Jang MH, Kim HJ, Kim EJ, Chung YR, Park SY.
    Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
    [Abstract] [Full Text] [Related]

  • 3. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B, Haller H, Mrklić I, Košta V, Čarić A, Tomić S.
    Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
    [Abstract] [Full Text] [Related]

  • 4. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
    Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J.
    Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
    [Abstract] [Full Text] [Related]

  • 5. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
    Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B.
    Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
    [Abstract] [Full Text] [Related]

  • 6. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S, Elstrand MB, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B.
    Cancer; 2005 Apr 15; 103(8):1631-43. PubMed ID: 15742334
    [Abstract] [Full Text] [Related]

  • 7. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL, Hsu CS, Liu WM, Lee YC, Lee YC, Chen CL.
    Int J Clin Exp Pathol; 2015 Apr 15; 8(5):5642-9. PubMed ID: 26191276
    [Abstract] [Full Text] [Related]

  • 8. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.
    Broner EC, Tropé CG, Reich R, Davidson B.
    Hum Pathol; 2017 Feb 15; 60():180-187. PubMed ID: 27825812
    [Abstract] [Full Text] [Related]

  • 9. Expression of Nestin and CD133 in serous ovarian carcinoma.
    Onisim A, Iancu M, Vlad C, Kubelac P, Fetica B, Fulop A, Achimas-Cadariu A, Achimas-Cadariu P.
    J BUON; 2016 Feb 15; 21(5):1168-1175. PubMed ID: 27837619
    [Abstract] [Full Text] [Related]

  • 10. Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions.
    Elloul S, Vaksman O, Stavnes HT, Trope CG, Davidson B, Reich R.
    Clin Exp Metastasis; 2010 Mar 15; 27(3):161-72. PubMed ID: 20213325
    [Abstract] [Full Text] [Related]

  • 11. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.
    Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA.
    Gynecol Oncol; 2014 Oct 15; 135(1):118-24. PubMed ID: 25093290
    [Abstract] [Full Text] [Related]

  • 12. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
    Kenda Suster N, Smrkolj S, Virant-Klun I.
    J Ovarian Res; 2017 Feb 23; 10(1):11. PubMed ID: 28231820
    [Abstract] [Full Text] [Related]

  • 13. MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma.
    Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B.
    Hum Pathol; 2016 Aug 23; 54():74-81. PubMed ID: 27063471
    [Abstract] [Full Text] [Related]

  • 14. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer.
    Figiel S, Vasseur C, Bruyere F, Rozet F, Maheo K, Fromont G.
    Hum Pathol; 2017 Mar 23; 61():26-32. PubMed ID: 27818287
    [Abstract] [Full Text] [Related]

  • 15. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B, Trope' CG, Wang TL, Shih IeM.
    Gynecol Oncol; 2006 Dec 23; 103(3):814-9. PubMed ID: 16844205
    [Abstract] [Full Text] [Related]

  • 16. Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma.
    Davidson B, Holth A, Dong HP.
    Virchows Arch; 2020 Nov 23; 477(5):677-685. PubMed ID: 32472195
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms.
    Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH.
    Pathol Int; 2006 Feb 23; 56(2):62-70. PubMed ID: 16445817
    [Abstract] [Full Text] [Related]

  • 20. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
    Miše BP, Telesmanić VD, Tomić S, Šundov D, Čapkun V, Vrdoljak E.
    Pathol Oncol Res; 2015 Apr 23; 21(2):347-56. PubMed ID: 25108408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.